US Patent Issued to TRT INNOVATIONS on March 31 for "177-Lu labeled peptide for site-specific uPAR-targeting" (Danish Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,171, issued on March 31, was assigned to TRT INNOVATIONS APS (Copenhagen, Denmark).

"177-Lu labeled peptide for site-specific uPAR-targeting" was invented by Andreas Kjaer (Frederiksberg, Denmark), Morten Persson (Copenhagen, Denmark) and Michael Ploug (Copenhagen, Denmark).

According to the abstract* released by the U.S. Patent & Trademark Office: "There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide."

The...